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ABSTRACT 
Nanospheres are the particles having the size range between 10-200 nm in diameter. Nanospheres can be amorphous or crystalline in nature 
and also they have the ability to protect the drug from enzymatic and chemical degradation. For the preparation of standard calibration curve of 
Mesalamine with Phosphate buffer pH 6.8 and Absorbance of µg/ml solution was measured between 200-400nm by using Shimadzu 1601 
UV/Vis double beam spectrophotometer. The Melting point of Mesalamine was determined using open capillary method. Infrared spectroscopy 
analysis of Mesalamine pure drug was performed by Fourier transfer infrared spectroscopy. Nanosphare containing Mesalamine were prepared 
using nanoprecipitation method. 200 mg of polymer (Eudragit RS and L) was dissolve in 50 ml water. Drug was dissolve in 20 ml of methanol. 
Both solution were mixed and add 50 ml of water and stirred for half an hour. Methanol and water was evaporated under reduced pressure 
using rotary flash evaporator until 10 ml of solution was remaining. Than this suspension was centrifuge at 15000 rpm at 40C for half an hour. 
The supernatant was discarded and remaining portion was washed with distilled water. The nano-sphares was dried over night at 600C and 
stored in desiccators. The surface morphology (roundness, smoothness, and formation of aggregates) and particle size was studied by scanning 
electron microscopy (SEM). Zeta potential of the best formulation (F4) was determined by zeta potential probe model DT- 300. Mesalamimne, 
Dextrose and Lactose were taken in required quantities mixed and granulating agent (Starch past) was added and passed through #40 sieves, 
then lubricant magnesium stearate and talc was added then compressed into tablets by rotary tablet punching machine. Then film coating is 
done by 6% w/v solution of Cellulose acetate Phthalate in isopropyl alcohol using 2% tween-80 as plasticizer in coating pan. The weight of 
tablet was kept constant for all formulations. Nanosphare tablet formulation F-2 Showed maximum drug (97.75%) released and formulation F-
4 showed 92.58% drug release. The In-vitro drug released study result showed that formulation F-2 96.58% drug was released after 17 hours 
which is highest drug release amongst all other tablet formulation. 
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1. INTRODUCTION: 
1.1 Nanosphere 
Nanoparticles can be divided into two main families: 
nanospheres, which have a homogeneous structure in the 
whole particle, and nanocapsules, which exhibit a typical 
core-shell structure. Nanospheres are the particles having 
the size range between 10-200 nm in diameter. Nanospheres 
can be amorphous or crystalline in nature and also they have 
the ability to protect the drug from enzymatic and chemical 
degradation. It has been shown that the hydrophobic 
surfaces of these particles are highly susceptible to 
opsonization and clearance by the reticulo endothelial 
system. The tiny capsule of drug store house is called vesicles 
and the solid skeleton structure is called Nanospheres. 
Biodegradable Nanospheres include albumin Nanospheres, 
modified starch Nanospheres, gelatin Nanospheres, 
polypropylene dextran Nanospheres and polylactic acid 
Nanospheres. In addition there are two more types of 
Nanospheres, immune Nanospheres and magnetic 
Nanospheres. Immuno-magnetic nanospheres can be 
prepared by combining the above two kinds of nanospheres, 
which could significantly improve its targeting. 
1.2Method of preparation of Nanospheres 
There are various types of method by which Nanospheres 
are prepared. 
 Polymerization (Emulsification polymerization) 
 Solvent Evaporation. 
 Solvent displacement technique. 
 Phase inversion temperature methods. 
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2. MATERIAL AND METHODS 
2.1 Preformulation studies of Mesalamine pure drug  
2.1.1 Preparation of standard calibration curve of 
Mesalamine 
10 mg of drug was dissolved in Phosphate buffer pH 6.8 and 
final volume was making up to 100 ml in 100 ml volumetric 
flask. The stock solution concentration was 100 mcg/ml 
obtained.  It was diluted with Phosphate buffer pH 6.8 to 
obtain solution in Concentration range10 to 60 µg/ml. 
Absorbance of µg/ml solution was measured between 200-
400 nm  by using Shimadzu 1601 UV/Vis double beam 
spectrophotometer. 
2.1.2 Melting point determination 
The Melting point of Mesalamine was determined using open 
capillary method. The capillary filled with drug powder was 
placed in Thiel’s tube containing liquid paraffin. The tube 
was heated and the melting point of the drug powder was 
noted. The average of three values was considered as the 
melting point of drug. 
2.1.3 FTIR Spectra of pure drug 
Infrared spectroscopy analysis of Mesalamine pure drug was 
performed by Fourier transfer infrared spectroscopy. 
2.2 Preparation of Nanosphare2 
Nanosphare containing Mesalamine were prepared using 
nanoprecipitation method. 200 mg of polymer (Chitocan, 
Pectin) was dissolve in 50 ml water. Drug was dissolve in 20 
ml of methanol. Both solution were mixed and add 50 ml of 
water and stirred for half an hour. Methanol and water was 
evaporated under reduced pressure using rotary flash 
evaporator until 10 Ml of solution was remaining. Than this 
suspension was centrifuge at 15000 rpm at 40C for half an 
hour. The supernatant was discarded and remaining portion 
was washed with distilled water. The Nanosphares was dried 
over night at 600C and stored in desiccators. 
 
Table 1 Formulation table of Nanosphare 
S. N. Material F-1 F-2 F-3 F-4 
1 Mesalamine (mg) 500 500 500 500 
2 Eudragite S 100 (mg) 250 500 - - 
3 Cellulose acetate Phthalate  (mg)   250 500 
4 Tween 80 (ml) 0.2 0.2 0.2 0.2 
5 Methanol (ml) 20 20 20 20 
6 Water (ml) 100 100 100 100 
 
2.3 Evaluation of Nanosphare 
2.3.1 Particle size, surface morphology and zeta 
potential13 
The surface morphology (roundness, smoothness, and 
formation of aggregates) and particle size were studied by 
scanning electron microscopy (SEM). Zeta potential of the 
best formulation (F4) was determined by zeta potential 
probe model DT- 300. 
2.3.2 Drug entrapment efficiency 13 
Drug content was determined by centrifugation method. The 
Nanosphare were redisperse by centrifugation in Phosphate 
buffer pH 6.8 at 15,000 rpm for 40 min at 250C to separate 
the free drug in the supernatant. Concentration of 
Mesalamine in the supernatant was determined by UV-Viss. 
spectrophotometyrically at 232 nm after suitable dilution. 
2.3.3 Fourier Transform Infra-red Spectroscopy (FT-IR) 
analysis 
The FT-IR spectra of pure Mesalamine Chitosan (F-2) 
Nanosphare were recorded to check drug polymer 
interaction and stability of drug. 
2.3.4 In -vitro release studies14 
In-vitro release studies were carried out by using dialysis 
tubes with an artificial membrane. Initial 3 hour the 
nanosphare of Mesalamine drug release study was 
conducted using 0.1 HCl as dissolution medium then the 
prepared Mesalamine Nanosphare and 10 ml of Phosphate 
buffer pH 6.8 was added to the dialysis tube and subjected 
todialysis by immersing the dialysis tube to the receptor 
compartment containing 250 ml of phosphate buffer pH 
6.8.The medium in the receptor was agitated continuously 
using a magnetic stirrer a temperature was maintained at 
37±10C. 5ml of sample of receptor compartment were taken 
at various intervals of time over a period of 24 h and each 
time fresh buffer was replaced. The amount of drug released 
was determined spectrometrically at 232 nm. 
2.4 Formulation of Mesalamine Nanosphare Tablet17 
Mesalamimne, Chitosan, Ethylcellulose, Dextrose and Lactose 
were taken in required quantities mixed and granulating 
agent (Starch past) was added and passed through #40 
sieves, then lubricant magnesium stearate and talc was 
added then compressed into tablets by rotary tablet 
punching machine. Then film coating is done by 6% w/v 
solution of Cellulose acetate Phthalate in isopropyl alcohol 
using 2% tween-80 as plasticizer in coating pan. The weight 
of tablet was kept constant for all formulations. A minimum 
of 100 tablets were prepared for each batch. 
 
 
 
 
 
Pachpute et al                                                                                                Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):1045-1053 
ISSN: 2250-1177                                                                                  [1047]                                                                                 CODEN (USA): JDDTAO 
Table 2 Polymer concentration of tablet formulation 
Sr. no Ingredient F-1 F-2 F-3 F-4 F-5 F-6 
1 Mesalamine Nanosphare 500 500 500 500 500 500 
2 Eudragite RS 25 50 75 - - - 
3 Eudragite L - - - 25 50 75 
4 Lactose   75 50 25 - - - 
5 Dextrose - - - 75 50 25 
6 Talc 5 5 5 5 5 5 
7 Magnesium Stearate 5 5 5 5 5 5 
8 Starch past qs Qs qs qs qs qs 
*All Quantities in milligram 
 
2.5 Drug Excipient compatibility study 
The interaction of the drug and the excipient was carried out 
by FTIR method to know the physiochemical interaction 
occur in the drug and excipient.The drug and excipients is 
taken in 1:5 ratios and placed in a vial and rubber stopper 
was placed on the vial and sealed properly for 6 month at 
400C±20C/75%RH±5%RH. 
2.6 Precompressed Parameter 
2.6.1 Bulk density18,19 
A quantity of 10 g of powder from each formulation, 
previously lightly shaken to break any agglomerates formed 
was introduced into a 50 ml measuring cylinder. The bulk 
volume and mass of the powder was determined. The bulk 
density was calculated using following formula:Bulk density= 
Weight of granules/ Volume of granules 
2.6.2 Tapped density18,19 
The measuring cylinder containing a known mass of blend 
was tapped for a fixed time. The minimum volume occupied 
in the cylinder and the mass of the blend was measured. The 
tapped density was calculated using the following formula:  
Tapped density= Weight of granules/ Volume of granules 
after 100 tapping 
2.6.3 Carrs Index18,19 
The simplest way for measurement of free flow of powder is 
compressibility, an indication of the ease with which a 
material can be induced to flow is given by Carr¡¦s index 
which is calculated as follows: 
Carr's index (%) = Tapped Density – Bulk Density/Tapped 
DensityX 100 
Where,BD = Bulk density, TD = Tapped density 
Table 3 Standards for Carr’s index 
Carr’s Index Flow 
5 – 15 Excellent 
12 - 16 Good 
18 – 21 Fair 
23 – 35 Poor 
35 – 38 Very poor 
More than 40 Extremely poor 
 
2.6.4 Hausners ratio18,19 
Hausners ratio value is less than 1.25 indicates good flow 
and greater than 1.5 indicates poor flow property which was 
calculated by using following formula:  
Hausnre's ratio = Tapped density/ Bulk density 
Table 4 Standards for Hausner ratio 
Hausner ratio Flow  
1.2 – 1.3 Excellent  
1.3 – 1.4 Good  
1.4 – 1.5 Fair  
1.5 – 1.6 Poor 
 
2.6.5 Angle of repose18,19 
It is determined by allowing a powder to flow through a 
funnel and fall freely on to a surface. Further addition of 
powder is stopped as soon as the pile touches the tip of the 
funnel. A circle is drawn around the pile without disturbing 
it. The height and diameter of the resulting cone are 
measured. The same procedure is repeated three times and 
the average value is taken. Angle of repose is calculated by 
using the following Formula: 
Tan θ = h/r Where, h = height of the powder cone; r = radius 
of the powder 
Table 5 Standards for Angle of Repose 
Average weight % difference 
130 mg or less 
130 – 324 mg 
324 mg and greater 
10 
7.5 
5 
 
2.6.6 Friability9 
For each formulations, preweighed tablet samples (20 
tablets) were placed on the ronche friabilator, the friabilator 
was rotated 25 RPM which is then operated for 100 
revolutions for 4 minute. The tablets were then dusted and 
reweighed. Conventional compressed tablets that loose less 
than 1.0% of their weight are considered acceptable. 
The % friability was then calculated by,%Friability = (W0 – 
W) / W0 x 100 
Where, F = friability W0 = initial weight of the ten tablets W = 
final weight of the ten tablets 
2.6.7 Hardness9 
Tablet hardness of each formulation was determined using a 
Monsanto hardness tester. Results were calculated from the 
average results of six tablets. 
2.6.8 Thickness9 
Tablet thickness is determined using vernier calipers in 
triplicate. 
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2.6.9 Disintegration test10 
The disintegration test was conducted by disintegration test 
apparatus. Introduce one tablet into each tube and add a disc 
to each tube. Suspend the assembly in the beaker containing 
the Phosphate buffer pH 6.8 and operate the apparatus for a 
specified period of time. The tablet passes the test if all 
tablets have disintegrated. If one or two tablets fail to 
disintegrate, repeat the test on 12 additional tablets, if 2 out 
of 18 tablet was fail to disintegrate after specific time the test 
is fail. 
2.6.10 In-vitro drug release studies11 
The study was conducted with six tablets for each 
formulation using USP type II dissolution apparatus and 900 
ml of 0.1 N HCl (First 3 hour) and Phosphate buffer pH6.8 as 
a dissolution medium at a paddle rotating speed of 75 rpm. 
Aliquots of 5 ml were withdrawn at selected time intervals 
through auto sampler and filtered through 0.45 filter and the 
same volume of dissolution medium was used to replace 
dissolution medium in order to maintain sink conditions. The 
absorbance of aliquots was measured at 232 nm using a 
UVspectrophotometer after appropriate dilutions. 
2.6.11 Stability Study 
The stability study was carried out for optimized formulation 
as per ICH guidelines. The nanoparticle of the best 
formulation were placed in screw capped glass container and 
stored at ICH storage (400C±20C/75%RH±5%RH) condition 
for a period of 60 days. The samples were analyzed for 
physical appearance and for the drug content. 
Table 6 ICH guidelines for stability study 
Study Storage condition Time period 
Long term 250C±20C/60%RH±5RH 12 month 
Intermediate 300C±20C/65%RH±5%RH 6 month 
Accelerated 400C±20C/75%RH±5%RH 6 month 
 
3. RESULT AND DISCUSSION 
3.1 Preformulation study of pure drug 
3.1.1 Calibration curve of Mesalaminein Phosphate 
buffer pH 6.8 
Phosphate buffer pH 6.8 was used for the preparation of 
Mesalamine concentration and absorption was measure by 
Shimadzu UV-1601 UV/Vis double beam spectrophotometer. 
The λ max of Mesalamine was found to be 232 nm. The result 
was showed in the table no. 8 and figure no. 1.  
 
 
Table 7  Standard CC of Mesalamine in  Phosphate buffer pH 6.8 
Sr. No. Concentration 
(g/ml) 
Absorbance Average 
Absorbance 1 2 3 
1 
2 
3 
4 
5 
6 
10 
20 
30 
40 
50 
60 
0.125 
0.292 
0.399 
0.574 
0.771 
0.918 
0.121 
0.287 
0.393 
0.569 
0.768 
0.915 
0.130 
0.292 
0.402 
0.579 
0.776 
0.921 
0.125 
0.292 
0.399 
0.574 
0.771 
0.918 
Correlation Co-efficient  (R²) = 0.9947 
Absorbance (y) = 0.159x conc - 0.0445 
  
 
Figure1Drug calibration curve in Phosphate buffer pH6.8 
3.1.2 Calibration curve of Mesalaminein 0.1 N HCl 
Mesalamine concentration was prepared in 0.1 N HCland 
absorption were measure by Shimadzu-1601 UV/Vis double 
beam spectrophotometer. The λ max of Mesalamine was 
found to be 232 nm. 
 
Figure 2Drug calibration curve in 0.1 N HCl 
3.1.3 Melting point: The average melting point of pure drug 
is 2830C which is complies with Stander melting point of 
drug. 
Table 8 Melting point of pure drug 
S. N. Melting point (0C) Average Melting Point (0C) 
1 284  
283 2 283 
3 283 
 
y = 0.0159x - 0.0445 
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3.1.4 FTIR Spectra of pure drug  
3.2 Drug excipient compatibility study of drug with Nanosphare polymer  
Table 9 Physical observation after 6 month 
S. No. Additives (50 mg each) with drug Physical 
Observation 
Observation at 450C 
after 6 month 
Remarks 
1. Drug ( Mesalamine) White No change Accepted 
2. Drug + Eudragite-S 100 White No change Accepted 
3. Drug +  Cellulose acetate Phthalate White No change Accepted 
 
3.3 Evaluation of Nanosphare 
3.3.1 Particle size, surface morphology and zeta potential 
 
(A) 
          
(B)                                                                                        (C) 
Figure 3- Scanning electron micrographs of (A) Nanosphare (B) Drug loaded nanosphare and (C) Polymer coated nanosphare 
3.3.2 Drug entrapment efficiency 
Drug entrapment efficiency of the formulations showed in 
the range of 90% to 96 %. The results have been shown in 
table. 
Table 10Drug Entrapment 
Sr. no. Batch no. % Entrapment 
1 F-1 94 
2 F-2 96 
3 F-3 92 
4 F-4 93 
 
 
 
Figure 4 Drug Entrapment
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3.3.4 In-vitro Drugrelease studies of Mesalamine nanosphare 
Table 11 In-vitro Drugrelease studies of Nanosphare 
Time (hr) F-1 F-2 F-3 F-4 
0 0.0 0.0 0.0 0.0 
1 0.21 0.15 0.31 0.95 
2 0.53 0.49 0.36 0.92 
3 1.49 1.72 1.26 1.76 
4 6.42 8.17 6.46 7.18 
5 19.72 22.26 20.85 21.39 
6 25.82 28.74 26.12 27.33 
7 31.29 36.76 33.32 35.27 
8 42.64 46.29 43.16 45.04 
9 53.32 56.61 54.88 55.16 
10 61.79 64.69 62.55 63.38 
11 69.21 73.57 71.21 72.15 
12 79.32 85.35 81.53 83.59 
13 88.52 91.67 89.23 90.09 
14 93.01 96.12 94.24 95.11 
15 93.13 96.24 94.35 95.26 
 
 
 
Figure 5 In-vitro Drugrelease studies of nanosphare 
3.4 Evaluation of Nanosphare Tablet 
3.4.1 Pre-compressed Parameter 
Table 12 Pre Compressed Parameter 
Formulation 
code 
Angle of Repose(0) Bulk density Tap density Hausner ratio Carr's Index 
F1 22016  ± 0.5547 0.376 ± 0.016 0.415± 0.002 1.16± 0.001 15.55± 0.612 
F2 20054  ± 0.6548 0.364 ± 0.014 0.438± 0.006 1.15± 0.001 12.92± 0.554 
F3 20028  ± 0.4568 0.374 ± 0.017 0.446± 0.002 1.16± 0.002 14.23± 0.532 
F4 21022  ± 0.5449 0.352 ± 0.013 0.423± 0.003 1.17± 0.004 13.64± 0.368 
F5 20018  ± 0.5226 0.353 ± 0.011 0.424± 0.002 1.15± 0.004 14.78± 0.408 
F6 21009  ± 0.8547 0.358 ± 0.019 0.442± 0.004 1.16± 0.003 13.80± 0.309 
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3.4.2 Post Compressed Parameter 
Table 13 Post Compressed Parameter 
Formulation 
code 
weight variation 
(mg) ± S.D 
Hardness 
(Kg/cm2) ± S.D 
Friability (%) ± 
S.D 
Thickness (mm) ± 
S.D 
F1 610 ± 1.11 5.1 ± 0.218 0.32 ± 0.04 5.18±0.017 
F2 608 ± 1.22 5.3 ± 0.225 0.32 ± 0.02 5.12±0.012 
F3 609± 1.01 5.2 ± 0.363 0.33± 0.03   5.17±0.013 
F4 611± 1.24 5.5 ± 0.106 0.31± 0.01   5.15±0.011 
F5 607± 1.42 5.4 ± 0167 0.34± 0.05   5.11±0.014 
F6 613± 1.51 5.3± 0.412 0.35± 0.06   5.14±0.012 
*Values mentioned are average of 3 determinations 
 
3.4.3 Drug content: 
Table 14 Drug Content 
Formulation Drug Content (%) 
F1 95.01 
F2 96.32 
F3 97.75 
F4 92.58 
F5 93.33 
F6 94.47 
 
 
Figure 6 Drug content of different formulation 
3.4.4 In-vitro drug release study of Mesalamine nanosphare tablet 
Table 15 Cumulative Drug release (F-1 to F-6) 
Time (hr) F-1 F-2 F-3 F-4 F-5 F-6 
0 0.0 0.0 0.0 0.0 0.0 0.0 
1 5.31 6.11 6.32 4.19 5.22 4.95 
2 9.36 10.42 11.63 5.19 6.31 8.92 
3 14.26 15.74 16.74 8.04 9.16 13.76 
4 18.46 20.13 22.56 12.49 14.34 17.18 
5 25.85 27.25 29.81 17.72 19.81 24.39 
6 31.12 33.74 35.88 22.35 23.09 30.33 
7 38.32 39.76 41.34 26.49 28.04 36.27 
8 45.16 46.29 48.73 32.57 34.33 43.64 
9 50.88 52.61 53.37 39.16 40.49 48.16 
10 55.55 57.69 59.88 45.63 46.45 54.38 
11 61.21 63.57 65.43 51.08 52.24 59.15 
12 67.53 69.35 70.55 56.31 57.58 64.59 
13 73.23 74.67 76.76 62.34 64.23 71.09 
14 82.05 83.53 82.34 69.73 71.54 81.32 
15 85.09 87.24 88.45 76.15 79.01 84.28 
16 93.91 94.85 96.57 87.89 89.12 92.95 
17 93.92 94.89 96.58 87.92 89.14 92.97 
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 Figure 7 Cumulative Drug release % (F-1 to F-6) 
3.4.5 Stability Study of optimized formulation 
Table 16 Comparison of drug release after 6 month 
Time (hr) Inital After 3 month 
0 0.0 0.0 
1 6.32 5.14 
2 11.63 9.87 
3 16.74 14.44 
4 22.56 20.32 
5 29.81 26.95 
6 35.88 34.01 
7 41.34 38.78 
8 48.73 45.89 
9 53.37 51.03 
10 59.88 57.05 
11 65.43 62.87 
12 70.55 67.59 
13 76.76 74.03 
14 82.34 79.84 
15 88.45 85.63 
16 96.57 93.94 
17 96.58 93.91 
 
 
Figure 8Comparative study ofdrug release after 6 month 
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4. CONCULSION 
On the basis of drug entrapment efficiency I concluded that 
method used for formulation of Nanosphare was optimized 
method. Formulation F-2 Showed 96% drug was entrapped 
which is best formulation among all other nanosphare 
formulation. Formulation F-3 showed least drug 
entrapment.In-vitro Drugrelease studies of Mesalamine 
nanosphare showed that Formulation F-2 release maximum 
drug (96.24%) after 15 hour.The FTIR spectra showed that 
drug and polymer used in formulation of Nanosphare tablet 
are compatible with each other.Nanosphare tablet 
formulation F-3 Showed maximum drug (97.75%) released 
and formulation F-4 showed 92.58% drug release.The In-
vitro drug released study result showed that formulation F-3 
96.58% drug was released after 17 hours which is highest 
drug release amongst all other tablet formulation. 
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